Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New "microcapsules" Put More Medication Into The Bloodstream To Treat Disease
Scientists are reporting a potential solution to a problem that limits the human body"s ability to absorb and use medications for heart disease, Type-2 diabetes, cancer and other conditions. It is a "nano-hybrid microcapsule" that enables the stomach to absorb more of these so-called "poorly-soluble" medicines. Their study is scheduled for the June 1 issue of ACS" Molecular Pharmaceutics, a bi-monthly journal.

American Cancer Society To Recognize Corporate Employers Changing The Course Of The Cancer Fight
The American Cancer Society - the nation"s leading voluntary health organization and largest non-governmental funder of cancer research and discovery - will present its Corporate Impact Awards June 19 during the Society-hosted Corporate Impact Conference in Chicago. The awards will recognize companies" engagement in targeted efforts to significantly impact cancer"s effect on the workplace, where disease-related expenditures and lost productivity costs annually surpass $228 billion; in contributing funds to the American Cancer Society to fight the disease; and in addressing responsible community involvement.
News of the day
NHS Confederation Responds To Public Accounts Committee Report On NHS Funding
Nigel Edwards, the director of policy at the NHS Confederation, said, "The surpluses generated by the NHS over the 2007-2008 financial year are a testament to sound financial planning and an awareness on the part of everyone in the service of the need to spend public money carefully.
Nutrition

Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal

Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark. Effective treatment options are available to treat rheumatic diseases, many of which have the potential to induce remission, defined as absence of signs or symptoms of disease. While there is evidence-based advice regarding when to initiate therapy in rheumatic diseases, there is no specific guidance on the timing of treatment withdrawal once a state of remission on medication is achieved. While this holds true for many autoimmune disease (such as Rheumatoid Arthritis, Crohn"s disease, Ulcerative Colitis, or Autoimmune Hepatitis), in the case of MTX therapy for JIA, a continuation of MTX for 12 to 24 months after induction of remission has been proposed by researchers.1 The risk of relapse in JIA patients, once MTX is discontinued, is approximately 50%.2 However, the results of this study have shown that continuing MTX therapy past the point of remission does not affect the risk of relapses after withdrawal of therapy. Clinical (disease subtype, duration or dosage of therapy, duration of MTX therapy) or standard laboratory tests (c-reactive protein and erythrocyte sedimentation rate as measurements of inflammation) could not differentiate between patients at-risk for relapse and those without this risk. However, MRP8/14 levels were significantly higher at MTX withdrawal in remission in those patients who subsequently developed relapses (715÷±140 ng/ml) compared to patients with stable remission (400÷±105 ng/ml; p=0.003). Levels of MRP8/14 were especially high in patients with relapses occurring within 6 months, compared to 12 months. (955÷±270 ng/ml; pJ Rheumatol 1995;22:1574-6]. 2 Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997;100:994-7]. Rory Berrie European League Against Rheumatism


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009